Radioactive iodine administration is not associated with improved disease-specific survival in classic papillary thyroid carcinoma greater than 4 cm confined to the thyroid

[1]  U. Megwalu,et al.  Thyroid Cancer Incidence and Mortality Trends in the United States: 2000 - 2018. , 2022, Thyroid : official journal of the American Thyroid Association.

[2]  Zhihui Li,et al.  The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer , 2020, PloS one.

[3]  T. Fahey,et al.  High‐dose radioactive iodine therapy is associated with decreased risk of recurrence in high‐risk papillary thyroid cancer , 2019, Surgery.

[4]  S. Devesa,et al.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 , 2017, JAMA.

[5]  Jee Soo Kim,et al.  Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma. , 2016, Endocrine-related cancer.

[6]  S. Filetti,et al.  Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. , 2015, The Journal of clinical endocrinology and metabolism.

[7]  S. Roman,et al.  Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. , 2015, The Journal of clinical endocrinology and metabolism.

[8]  John T. Chang,et al.  The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. , 2010, Thyroid : official journal of the American Thyroid Association.

[9]  L. Davies,et al.  Thyroid cancer survival in the United States: observational data from 1973 to 2005. , 2010, Archives of otolaryngology--head & neck surgery.

[10]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[11]  David D. Smith,et al.  Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope , 2007, Journal of surgical oncology.

[12]  C. Kwan,et al.  Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. , 2006, Endocrine-related cancer.

[13]  R. Tsang,et al.  Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years , 2005, Clinical endocrinology.

[14]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[15]  R. Tsang,et al.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma , 1998, Cancer.

[16]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[17]  L. Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.